文献速递中毒与环境急症重症综合管理与镇静镇痛

苯巴比妥方案治疗酒精戒断综合征的系统评价与Meta分析

Evaluation of phenobarbital based approach in treating patient with alcohol withdrawal syndrome: A systematic review and meta-analysis.
PubMed 文献 · Am J Emerg Med · 2023-04-05
一句话结论Meta分析显示苯巴比妥治疗酒精戒断综合征的插管率、癫痫发作率及住院/ICU住院时间与苯二氮䓬类相似,但证据主要来自观察性研究且异质性显著。

该系统评价与Meta分析检索PubMed、Scopus和Web of Science数据库至2022年6月30日,纳入12项研究共1934例在急诊科和/或ICU治疗的酒精戒断综合征成人患者,其中765例(41.7%)接受苯巴比妥治疗,1169例(58.3%)接受其他方式治疗。主要结局插管风险在苯巴比妥组与对照组间相似(RR 0.70,95% CI 0.36-1.38,P=0.31)。癫痫发作率(RR 0.73,95% CI 0.29-1.89)、住院时间(SMD -0.02,95% CI -0.26, 0.21)和ICU住院时间(SMD -0.02,95% CI -0.21, 0.25)在两组间也相似。作者指出,由于纳入研究多为观察性研究且异质性显著,需要方法学严谨的进一步试验。

要点

  • 在急诊和/或ICU治疗的酒精戒断综合征成人患者中,苯巴比妥组与苯二氮䓬类组的插管风险相似(RR 0.70,95% CI 0.36-1.38,P=0.31)。
  • 苯巴比妥组与苯二氮䓬类组的癫痫发作率相似(RR 0.73,95% CI 0.29-1.89)。
  • 苯巴比妥组与苯二氮䓬类组的住院时间(SMD -0.02,95% CI -0.26, 0.21)和ICU住院时间(SMD -0.02,95% CI -0.21, 0.25)相似。
  • 共纳入12项研究1934例患者,其中765例(41.7%)接受苯巴比妥治疗,1169例(58.3%)接受其他方式治疗。
  • 作者认为,由于纳入研究多为观察性研究且异质性显著,需要方法学严谨的进一步试验。

适用人群与场景

  • 在急诊科就诊并被诊断为酒精戒断综合征的成人患者,在急诊科和/或ICU接受治疗。

研究设计与关键结果

  • 系统评价与Meta分析,纳入12项研究共1934例酒精戒断综合征成人患者,其中765例(41.7%)接受苯巴比妥治疗,1169例(58.3%)接受其他方式治疗。
  • 主要结局:苯巴比妥组与对照组插管风险相似(RR 0.70,95% CI 0.36-1.38,P=0.31)。
  • 次要结局:苯巴比妥组与苯二氮䓬类组癫痫发作率相似(RR 0.73,95% CI 0.29-1.89)。
  • 次要结局:苯巴比妥组与苯二氮䓬类组住院时间相似(SMD -0.02,95% CI -0.26, 0.21)。
  • 次要结局:苯巴比妥组与苯二氮䓬类组ICU住院时间相似(SMD -0.02,95% CI -0.21, 0.25)。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析,纳入随机试验和观察性(前瞻性或回顾性)研究。
  • 局限:纳入研究多为观察性研究,且研究间存在显著异质性;需要方法学严谨的进一步试验。

对床旁实践的改变

  • 作者认为,苯巴比妥治疗酒精戒断综合征患者的插管率、ICU住院时间或住院时间与苯二氮䓬类治疗相似;但由于纳入研究多为观察性研究且异质性显著,需要方法学严谨的进一步试验。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Alcohol Withdrawal Syndrome (AWS) among patients with chronic and heavy alcohol consumption can range from mild to severe and is associated with high morbidity and mortality. Currently, treating AWS with benzodiazepines is the standard of care, but phenobarbital has also been hypothesized to be an effective first-line treatment due to its pharmacological properties and mechanism of action. We conducted a meta-analysis to review relevant literature and compare the clinical outcomes for patients diagnosed with AWS in ED and ICU settings.

METHODS: We performed a literature search in in the PubMed, Scopus, and Web of Science databases from inception to June 30, 2022. Randomized trials and observational (prospective or retrospective) studies were eligible if they included adult patients who presented in the ED and were treated in the ED and/or the intensive care unit (ICU) with a diagnosis of AWS. The primary outcome was the rate of intubation among patients who received phenobarbital, compared with benzodiazepines. Secondary outcomes such as rates of seizures, hospital, and ICU length of stay (LOS), also were included. The PROSPERO registration is CRD42022318862.

RESULTS: We included twelve studies (1934 patients) in our analysis. Of the 1934 patients in these studies, 765 (41.7%) were treated with phenobarbital and 1169 (58.3%) were treated with other modalities for alcohol withdrawal. Treating AWS patients with phenobarbital did not affect their risk for intubation, as the risk for intubation was similar between the phenobarbital and the control group (RR 0.70, 95% CI 0.36-1.38, P = 0.31). In addition, patients who were treated with phenobarbital were found to have similar rates of seizures (RR 0.73, 95% CI 0.29-1.89) and length of stay in the hospital (Standardized Mean Difference -0.02, 95% CI -0.26, 0.21) or the ICU (SMD -0.02, 95% CI -0.21, 0.25) when compared with patients receiving benzodiazepines.

CONCLUSIONS: Management of patients with AWS with phenobarbital is associated with similar rates of intubation, length of stay in the ICU, or length of stay in the hospital as treatment with benzodiazepines. However, due to the inclusion of mostly observational studies and a significant level of heterogeneity among the studies assessed in this review, additional trials with strong methodology are needed.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Pourmand A, AlRemeithi R, Kartiko S, et al. Evaluation of phenobarbital based approach in treating patient with alcohol withdrawal syndrome: A systematic review and meta-analysis. Am J Emerg Med. 2023. PMID: 37060631. doi:10.1016/j.ajem.2023.04.002

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。